“...pleasure and pain, they come and go and don't last... bear them patiently”
—Gita
Pathos InvestmentsEquity Research
Research  ›  Fact Sheets  ›  RVTY

REVVITY, INC.

LISTEDNYSE
SYMBOLRVTY
SIC3826
STATE OF INC.MA
FISCAL YEAR ENDSDecember 29
CIK31791

LABORATORY ANALYTICAL INSTRUMENTS · LARGE ACCELERATED FILER · 10 FISCAL YEARS OF SEC XBRL DATA, 2017–2025

REVENUES, NET INCOME AND FREE CASH FLOW BY FISCAL YEAR$ billions012342017201720182019202120222023202320242025RevenuesNet incomeFree cash flowEARNINGS AND DIVIDENDS PER SHARE$ per share0.002.505.007.5010.002017201720182019202120222023202320242025EPS dilutedDividends per share

Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.

CAPITALIZATION 12/28/25

($ millions)Amount%
Total debt3,23930.9
Stockholders' equity7,25069.1
Total capitalization10,490100.0

111,586,401 shares outstanding at 6 August 2026 (cover page of the 10-Q filed 11 August 2026).

LONG-TERM DEBT 12/28/25

($ millions)Amount
Long-term debt, incl. current maturities3,239
Long-term debt, noncurrent2,631
Current maturities589

CAPITAL STOCK 12/28/25

Common shares authorized300,000,000
Common shares issued112,281,000
Par or stated value per share ($)1
Preferred stock ($ millions)0
Outstanding at 8/6/26111,586,401

DIVIDENDS DECLARED/PAID

Fiscal yearPer share $Payout %
20250.2813.5
20240.2812.7
20230.285.0
20230.286.2
2022––

HISTORY AND BUSINESS

HISTORY: Incorporated in Massachusetts. Formerly known as PERKINELMER INC (to 14 April 2023); EG&G INC (to 26 July 1999).

BUSINESS: Classified by the SEC under Standard Industrial Classification 3826, Laboratory Analytical Instruments. Large accelerated filer. Principal executive office: 77 4Th Avenue, Waltham, MA 02451. Fiscal year ends December 29. For a description of the business, see Item 1 of the latest 10-K.

CONSOLIDATED INCOME ACCOUNT, YEARS ENDED

($ millions)12/28/2512/29/2412/31/23
Revenues2,8562,7552,751
Research and development216197217
Selling, general and administrative9929941,023
Depreciation and amortization405428432
Operating income357347301
Interest expense929699
Income before income taxes268316183
Income taxes28333
Net income241270693
Earned per share, diluted ($)2.072.205.55
Dividends per share ($)0.280.280.28

CONSOLIDATED BALANCE SHEET

($ millions)12/28/2512/29/24
Cash and equivalents9201,163
Receivables, net745632
Inventories379368
Total current assets2,2402,350
Property, plant and equipment, net479482
Goodwill6,6136,464
Total assets12,16812,392
Total current liabilities1,331653
Long-term debt2,6313,150
Total liabilities4,9184,726
Stockholders' equity7,2507,667
Total liabilities and equity12,16812,392

TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)

Fiscal year endedRevenuesOper. incomeNet incomeNet margin %EPS diluted $Div. per share $Oper. cash flowCapital expend.Free cash flowTotal assetsTotal liabilitiesTotal debtStockholders' equityROE %Debt / equity
12/28/252,8563572418.42.070.285837450912,1684,9183,2397,2503.30.45
12/29/242,7553472709.82.200.286288754212,3924,7263,1727,6673.50.41
12/31/232,75130169325.25.550.2891811013,5655,6923,9007,8738.80.50
1/1/233,31274356917.24.500.286808659414,1306,7474,3947,3837.70.60
1/2/223,8281,25894324.68.08–1,411861,32515,0017,8594,9847,14113.20.70
1/3/213,78386772819.26.490.28892648297,9604,2251,9913,73519.50.53
12/29/192,8843622287.92.040.28363762876,5393,7252,0742,8148.10.74
12/30/182,7783242388.62.130.28311932185,9763,3911,8912,5859.20.73
12/31/172,25729629313.02.640.28288392496,0913,5882,0062,50311.70.80
1/1/172,11629523411.12.120.28351323194,2772,1231,0462,15410.90.49

Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.

REGISTRANT:

REVVITY, INC.
CIK 31791 · EIN 04-2052042

PRINCIPAL OFFICE:

77 4Th Avenue, Waltham, MA 02451
Tel.: 781-663-6900

INCORPORATED:

Massachusetts

INDUSTRY (SEC SIC CODE):

3826 · Laboratory Analytical Instruments

FILER STATUS:

Large accelerated filer

LATEST ANNUAL REPORT:

10-K for period ended 12/28/25, filed 24 February 2026

FORMER NAMES:

PERKINELMER INC; EG&G INC

RECENT FILINGS (ANNUAL REPORT REFERENCES BELOW):

8/11/2610-Qperiod 7/5/26
8/4/268-Kperiod 8/4/26
5/12/2610-Qperiod 4/5/26
5/5/268-Kperiod 5/5/26
5/1/268-Kperiod 4/28/26
3/16/26DEF 14Aperiod 4/28/26
2/24/2610-Kperiod 12/28/25
2/2/268-Kperiod 2/2/26

Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/24/26) · 10-K FY2024 (filed 2/25/25) · 10-K FY2023 (filed 2/27/24) · 10-K FY2022 (filed 3/1/23) · 10-K FY2021 (filed 3/3/22) · 10-K FY2020 (filed 3/2/21) · 10-K FY2019 (filed 2/25/20) · 10-K FY2018 (filed 2/26/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.

Data from SEC filings. © 2026 Pathos Investments · pathosinvestments.com · For educational purposes only. Not investment advice.

Data from SEC filings  ·  Educational only  ·  Not investment advice